Clinical commissioning policy statement, and accompanying documents, for the treatment for defined patients with rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB, pre-extensively drug-resistant (pre-XDR) TB and extensively drug-resistant (XDR-TB) including bedaquiline and delamanid (all ages)